Goal
Provide a pharmaceutical or dietary-supplement composition to treat neuromuscular and other diseases, including Lyme disease.
Problem
Neuromuscular degeneration, chronic inflammation, infectious diseases such as Lyme disease, and a broad list of disorders (fibromyalgia, MS, RA, Alzheimer's, etc.).
Concept Summary
The invention describes an anhydrous copper complex (C12H10ClCuN2O4) that can be administered orally or pharmaceutically to alleviate symptoms of many neuromuscular and infectious diseases. The copper complex is claimed to have anti-inflammatory, antimicrobial, and neuro-protective properties.
Principles
- Copper-based antimicrobial activity
- Anti-inflammatory chemical action
- Neuro-protective effects of copper ions
Scientific Domains
Materials
- Copper(I) chloride
- Organic ligand (C12H10ClCuN2O4)
- Excipient compounds (e.g., diluents, binders)
Mechanisms of Action
- Copper ion disrupts bacterial metabolism
- Modulation of inflammatory pathways
- Support of mitochondrial function in muscle cells
Applications
- Treatment of Lyme disease
- Management of neuromuscular disorders
- Adjunct therapy for inflammatory conditions
Claimed Performance
The composition is claimed to treat or reduce symptoms of a wide range of diseases, including Lyme disease, fibromyalgia, multiple sclerosis, rheumatoid arthritis, Alzheimer's, and many others.
Experimental Evidence
SEM images and mass-spectrometry data (Figures 1-9) confirm the chemical structure of the copper complex; no clinical trial data are presented.
Limitations
- No peer-reviewed clinical data provided
- Regulatory approval status unknown
- Dosage and safety profile not fully described
Red Flags
- Claims of broad therapeutic benefit without clinical evidence
- Potential for copper toxicity if mis-dosed
